Fluoride helps prevent cavities when applied topically to the teeth, but when ingested can pose significant risks, even kill ...

As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...

The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy ...

Sanofi (SYN) 43rd Annual J.P. Morgan Healthcare January 14, 2025 12:45 PM ETCompany ParticipantsPaul Hudson - Chief Executive OfficerFrancois-Xavier Roger ...

Immunovant secures $450M private placement for IMVT-1402 development, while Biomea shifts focus to diabetes, and multiple companies announce deals and organizational changes.

French drug major Sanofi (SNY) announced Monday that its Sarclisa has obtained first approval in China for the treatment of adult ...

Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myelomaApproval based on ...

The trial enrolled 531 adult subjects with multiple myeloma who had received at least one previous line of therapy.

Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...

Looking into the current session, Sanofi Inc. SNY shares are trading at $49.35, after a 0.24% increase. Moreover, over the ...

Sanofi's phase 3 study shows Sarclisa SC matches IV formulation in efficacy for relapsed myeloma. Regulatory submissions are planned for 2025.

As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up ...